Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇▇▇▇▇▇▇▇▇▇ Warrants") to purchase that number of shares of common stock of the Company equal to 5.0% of the aggregate number of shares of common stock placed in the Offering (and if the Offering includes a "greenshoe" or "additional investment" option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the Offering is commenced (such price, the "Offering Price"). If no warrants are issued to investors in the Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "“▇▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.06.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Axsome Therapeutics, Inc.)
Warrant Coverage. The Company shall issue to ▇W▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇“W▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.07.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇W▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇W▇▇▇▇▇▇▇▇▇, have a term of five four (54) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Stellar Biotechnologies, Inc.)
Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "“▇▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.0% of the aggregate number of shares of common stock placed in the Offering (and if the Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇W▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇“W▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇W▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇W▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇W▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇“W▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.08.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇W▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇W▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "“▇▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.03.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Bellerophon Therapeutics, Inc.)
Warrant Coverage. The Company shall issue to ▇W▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇“W▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.03.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇W▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇W▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share of common stock (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇W▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇W▇▇▇▇▇▇▇▇▇, have a term of five three (53) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "“▇▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.07.5% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract
Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "“▇▇▇▇▇▇▇▇▇▇ Warrants"”) to purchase that number of shares of common stock of the Company equal to 5.04.0% of the aggregate number of shares of common stock placed in the each Offering (and if the an Offering includes a "“greenshoe" ” or "“additional investment" ” option component, such number of shares of common stock underlying such additional option component, with the ▇▇▇▇▇▇▇▇▇▇ Warrants issuable upon the exercise of such option). If the Securities included in the an Offering are convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the Offering Price (as defined hereunder). The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such ▇▇▇▇▇▇▇▇▇▇ Warrants shall have an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date the an Offering is commenced (such price, the "“Offering Price"”). If no warrants are issued to investors in the an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of five (5) years and an exercise price equal to 125% of the Offering Price.
Appears in 1 contract